# Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

> **NCT00039325** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** dendritic cell-MART-1 peptide vaccine

## Key facts

- **NCT ID:** NCT00039325
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2005-09
- **Final completion:** 2009-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039325, "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00039325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*